Houston Methodist. Leading Medicine.
Houston Methodist. Leading Medicine

Kenji Yokoi M.D., Ph.D.

Kenji Yokoi, M.D., Ph.D.

 Kenji Yokoi, M.D.,Ph.D.

Kenji Yokoi, M.D., Ph.D.

Assistant Member 
Department of Nanomedicine
The Methodist Hospital Research Institute

Visiting Scientist
Department of Cancer Biology
The University of Texas MD Anderson Cancer Center
Guest Researcher
Cancer Research Institute, Kanazawa University, Kanazawa, Japan

E-mail: kyokoi2@houstonmethodist.org
Phone: 713-441-0448
Fax: 713-441-7834


Education

M.D.   Kanazawa University School of Medicine, Kanasawa, Japan (Medicine)
Ph.D.   Kanazawa University Graduate School of Medicine, Kanazawa, Japan (Biology)
     

Postdoctoral Training

Research Fellow, University of Texas MD Anderson Cancer Center (Cancer Biology)

Residency, Kanazawa University Hospital, Kanazawa, Japan (Surgery)

Biography

Dr. Yokoi received his M.D. degree in 1992 and Ph.D. degree in 1997 from the Kanazawa University, School of Medicine and Graduate School of Medicine respectively. Dr. Yokoi completed his postgraduate research fellowship at the University of Texas MD Anderson Cancer Center in Houston, TX. He then accepted a position as an instructor in the Department of Cancer Biology at MD Anderson and as an instructor of general and cardiothoracic surgery for Kanazawa University Hospital in Japan.

He was appointed to the position of assistant professor in the department of cancer biology at MD Anderson in 2007 and then as an assistant member in the department of nanomedicine in The Methodist Hospital Research Institute in 2011. Dr. Yokoi has also held the position of visiting scientist in the department of cancer biology at MD Anderson since 2011 and guest researcher for the Cancer Research Institute of Kanazawa University since 2008-present.

Description of Research

Dr. Yokoi’s develops novel therapies and imaging techniques for cancer using nanotechnologies. His basic research program defines the structure-permeability of tumor associated vessels to nanoparticles using various orthotopic mouse models of cancer. The over goal of these studies is to develop personalized therapy for cancer based on selection strategies that define the optimal drug loaded nanoparticles for a patient, based on the biodistribution properties of nanoparticles.

Major Areas of Research

Cancer Biology, drug delivery, nanotechnology, imaging, nanomedicine

Recent Publications

Brantley EC, Guo L, Zhang C, Lin Q, Yokoi K, Langley RR, Kruzel E, Maya M, Kim SW, Kim SJ, Fan D, Fidler IJ. Nitric Oxide-mediated tumoricidal activity of murine microglial cells. Transl Oncol. 2010;3(6):380-8. PMID: 21151477

Yokoi K, Hawke D, Oborn CJ, Jang JY, Nishioka Y, Fan D, Kim SW, Kim SJ, Fidler IJ. Identification and validation of SRC and phospho-SRC family proteins in circulating mononuclear cells as novel biomarkers for pancreatic cancer. Transl Oncol 2011;4(2):83-91. PMID: 21461171

Sun Y, Yokoi K, Li H, Gao J, Hu L, Liu B, Chen K, Hamilton SR, Fan D, Sun B, Zhang W. NGAL Expression is elevated in both colorectal adenoma-carcinoma sequence and cancer progression and enhances tumorigenesis in xenograft mouse models. Clin Cancer Res 2011;17(13):4331-40. PMID: 21622717